MingCeler’s principal scientist

Dr. Guangming Wu, PhD

Dr. Guangming Wu, professor of Guangzhou Bio-land Laboratory, worked as a research associate or postdoctoral fellow at the New England Medical Animal Center, Brown University, University of Missouri-Columbia, Temple University School of Medicine, and other internationally renowned research institutions. In 2004, he joined the Max Planck Institute for Molecular Biology (MPI) in Germany, where he worked with Prof. Hans R. Schöler (Member of the German National Academy of Sciences) on the development of mouse embryos and stem cell mechanisms.

Dr. Wu has been working on the molecular mechanisms of human, porcine, bovine, and mouse oocyte and early embryonic development, and the establishment of totipotency and pluripotency for more than 30 years, and is well versed in various embryonic in vitro culture and micro manipulation techniques. He is the first and currently the only scientist to increase the birth rate of mice derived from tetraploid compensation technology from 1-5% to 30-60% through optimization, achieving industrialization of the technology. He has co-authored 79 SCI papers with a combined impact factor of over 670 and over 7150 citations and has published in top international journals such as Nature, Cell stem cell, etc.

For his outstanding contribution to embryo manipulation, Dr. Wu’s name is permanently displayed in Munich’s Deutsches Museum, which is the world's largest science and technology museum.

In August 2019, Dr. Wu was introduced back into China as a full-time researcher, he and his research team successfully constructed an ACE2 humanized mouse model within 35 days, laying an experimental "foundation" for the research of COVID-19 pathogenesis, drug screening, and vaccine development. Due to his brilliant achievements in science and technology, Dr. Wu was awarded "Advanced Individual in Fighting against COVID-19 in Guangdong Province" in 2020.

The successful development and application of the most advanced next-generation Tetraploid Complementation technology (TurboMice™ technology) in mouse modeling during the fight against COVID-19, encourage Dr. Wu to strive for greater value in the development of biopharmaceuticals. Therefore, he co-founded Guangzhou MingCeler Biotech Co., Ltd as principal scientist, committing to the transformation of TurboMice™ technology from the laboratory to industrial applications to provide high-end model mice products and services for global universities, research institutes, hospitals, and pharmaceutical companies involved in life health research.